Overview
NICE is unable to make a recommendation about the use in the NHS of canakinumab for systemic juvenile idiopathic arthritis. This is because Novartis did not provide an evidence submission.
Last reviewed: 27 November 2013
Next review: We will review this decision if the company decides to make a submission.